Sarah Pringle
More than a decade into its investment, L Catterton is hashing out a deal to sell PatientPoint, a provider of point-of-care healthcare advertising and education, according to two sources familiar with the matter.
Commercial banks are increasingly evaluating opportunities to buy boutique M&A firms as they look to add capabilities in dealmaking areas like healthcare, according to a senior banker at Freeman & Co, a boutique firm which specializes in selling other boutique investment banking franchises. If he had to choose, the healthcare, technology and consumer industries are […]
Nvision Eye Centers, a founder-owned provider of Lasik and cataract surgery, is evaluating a potential sale, according to four sources. Harris Williams has been retained to provide financial advice to the Aliso Viejo, California company, three of the sources said. It is unclear if a process has formally launched. One of the sources added that […]
No spooking investors from animal health
Frazier Healthcare Partners hired Norwest Equity Partners’ Christina Miller Reszka and promoted two members of the Seattle firm’s investment team, Buyouts has learned. Reszka joined Frazier as a principal within its growth buyout practice, according to a source. Frazier’s second pool of capital focused exclusively on growth buyouts, Frazier Healthcare Growth Buyout Fund IX, raised $780 […]
FFL Partners has kicked off a sales process for EyeCare Partners, a hybrid optometry and ophthalmology provider, according to several sources familiar with the matter. The St. Louis vision care company expects to field initial bids over the next couple weeks, with a deal likely to be signed by mid- to late-December, two of the […]
European firms prove a force to reckon with in eClinical
TPG Capital is investing in Kelsey-Seybold Clinic, a doctor-owned integrated healthcare organization in the greater Houston area, according to three sources familiar with the matter.
Astorg has joined eResearchTechnology’s existing investor base in a transaction valuing the fast-growing clinical trial technology company at approximately $3.8 billion, Buyouts has learned.
Almost two years after emerging from Chapter 11 bankruptcy, 21st Century Oncology is evaluating a sale that could ultimately value the newly-led cancer treatment company around $1 billion, according to people familiar with the matter.